References
1. Tayal U, Prasad S and Cook SA. Genetics and genomics of dilated cardiomyopathy and systolic heart failure. Genome Med . 2017;9:20.
2. Thomas T, Nancy, Haase,Wayne et al . Heart disease and stroke statistics–2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation . 2006;113:85-151.
3. Halliday BP, Cleland JGF, Goldberger JJ et al . Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future. Circulation . 2017;136:215-231.
4. Sun WP, Li CL, Guo JC et al . Long-term efficacy of implantable cardiac resynchronization therapy plus defibrillator for primary prevention of sudden cardiac death in patients with mild heart failure: an updated meta-analysis. Heart Fail Rev . 2016;21:447-53.
5. Pathak RK, Sanders P and Deo R. Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy. Eur Heart J . 2018;39:2859-2866.
6. Kolodziejczak M, Andreotti F, Kowalewski M et al . Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis. Ann Intern Med . 2017;167:103-111.
7. Ponikowski P, Voors AA, Anker SD et al . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.Eur Heart J . 2016;37:2129-2200.
8. Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al , Task Force for the Management of Patients with Ventricular A and the Prevention of Sudden Cardiac Death of the European Society of C. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).Europace . 2015;17:1601-87.
9. Bansch D, Antz M, Boczor S et al . Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation . 2002;105:1453-8.
10. Steinberg BA, Al-Khatib SM, Edwards R et al . Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail . 2014;2:623-9.
11. Kober L, Thune JJ, Nielsen JC et al . Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.N Engl J Med . 2016;375:1221-30.
12. Sticherling BASMSKDBSOC. Application of a mortality risk score in a general population of patients with an implantable cardioverter defibrillator (ICD). Heart . 2014;100:487-491.
13. Barsheshet A, Moss AJ, Huang DT et al . Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol . 2012;59:2075-9.
14. Investigators TAvIDA. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. The New England journal of medicine . 1997;337:1576-1584.
15. Hjalmarson A GS, Fagerberg B, Wedel H et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA . 2000;283:1295-1302.
16. Saba S, Atiga WL, Barrington W et al . Selected patients listed for cardiac transplantation may benefit from defibrillator implantation regardless of an established indication. The Journal of Heart and Lung Transplantation . 2003;22:411-418.
17. Ermis C ZG, Zhu AX, Fabian W et al . Improved survival of cardiac transplantation candidates with implantable cardioverter defibrillator therapy: role of beta-blocker or amiodarone treatment.J Cardiovasc Electrophysiol . 2003;14:1540-1546.
18. Wells G PR, Healey JS, Talajic M et al . Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. Canadian Medical Association Journal . 2011;183:421-429.
19. Bilchick KC, Kamath S, DiMarco JP et al . Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation . 2010;122:2022-30.
20. Sohaib SM, Finegold JA, Nijjer SS et al . Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials. JACC Heart Fail . 2015;3:327-36.